From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success

Last Updated: Wednesday, January 19, 2022

This report provides up-to-date information on outcomes and adverse effects from published and presented clinical trials of CAR-T cell therapy for AML and provides the preclinical rationale underlying these studies and antigen selection. The authors highlight currently active clinical trials and the potential improvements and caveats with these novel approaches.

BioDrugs
Advertisement
News & Literature Highlights

Journal of Medical Cases

Cyclophosphamide for the treatment of refractory immune effector cell-associated neurotoxicity syndrome following CD19-targeted CAR T-cell therapy

Transplantation and Cellular Therapy

Financial toxicity in a phase I/II trial of LV20.19 CAR-T cell for B-cell malignancies a longitudinal, qualitative study

Experimental Biology and Medicine

Chimeric antigen receptor natural killer cell therapy for solid tumors: Mechanisms, clinical progress, and strategies to overcome the tumor microenvironment

Frontiers in Immunology

Impact of inotuzumab ozogamicin as bridging therapy and tumor burden in CAR-T therapy for B-acute lymphoblastic leukemia

Blood

Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma

Mayo Clinic Proceedings. Innovations, Quality, & Outcomes

Operationalizing access for chimeric antigen receptor T cell therapies: A cross-functional perspective

World Journal of Oncology

Neurotoxicity of immunotherapy: Immune checkpoint inhibitor-related encephalitis vs. immune effector cell-associated neurotoxicity syndrome

Clinical and Translational Oncology

Emerging strategies to reduce the side effects of CAR-T cell therapy: Focusing on gene editing and nanotechnology

Transplantation and Cellular Therapy

Best practice considerations by the American Society of Transplant and Cellular Therapy: Infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies

Blood Advances

CAR T-cell toxicities: From bedside to bench, how novel toxicities inform laboratory investigations

Advertisement
Advertisement